| ²é¿´: 1980 | »Ø¸´: 13 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
liu02love½ð³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÈûÀ´Îô²¼ÔÓÖÊ
|
||
|
ÇëÎʸ÷λ´óÉñ£¬Ò©Æ·ÒÑÖªÔÓÖʾ¿¾¹Êǰ´±ê×¼£¨ÀýÈ磬ҩµä±ê×¼£©À´£¬»¹Êǰ´±¨µÀµÄÎÄÏ×À´£¿ ˳±ãÎÊÏÂÈûÀ´Îô²¼µÄÒÑÖªÔÓÖÊÊÇÄÄЩ£¿Êǰ´Ò©µä±ê×¼£¿£¨Ã²ËÆÒ©µäֻ˵ÁË2¸ö A,B£©ÎªÊ²Ã´³öÊÛµÄC,D,E,F,GÊÇÔõô»áµÄÊ£¿ [ À´×Ô¿ÆÑмÒ×å Ò©Îﻯѧ¼Ò×å ] |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
Ñз¢µÄÍÆ½øÆ÷ |
» ²ÂÄãϲ»¶
¶þÌǵÄÌÇÖ¬£¬ºÏ³Éºósephadex LH-20·ÖÀë²»³öÀ´£¬ÇóÖú
ÒѾÓÐ1È˻ظ´
ÄÏ·½Ò½¿Æ´óѧÖé½Ò½ÔºÐ¤¼ÆÉú¿ÎÌâ×éÕÐÊÕ²©Ê¿Éú £¨2026ÄêÈëѧ£©
ÒѾÓÐ2È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ190È˻ظ´
349ҩѧר˶105500Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
½Î÷¿Æ¼¼Ê¦·¶´óѧ΢ÉúÎïÌìȻҩÎïÀÏʦ½éÉÜ
ÒѾÓÐ23È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
298Çóµ÷¼ÁÒ»Ö¾Ô¸Öк£Ñó
ÒѾÓÐ3È˻ظ´
292ҩѧµ÷¼Á
ÒѾÓÐ1È˻ظ´
ҩѧµ÷¼ÁÉêÇë×Ô¼öÐÅ£¬Ò»Ö¾Ô¸ÖÐÄÏ´óѧ
ÒѾÓÐ1È˻ظ´
ҩѧ349ר˶Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
¡¶×óÒÒÀÎ÷̹עÉäÒºÖÆ±¸¹¤ÒÕÑо¿¡¢ÖÊÁ¿¿ØÖƺÍÎȶ¨ÐÔÑо¿¡·ÏÂÔØ
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÇëÎÊ£¬ÈûÀ´Îô²¼ÄÜ·ñÓÃ×ÏÍâ¼ì²â£¿
ÒѾÓÐ4È˻ظ´
MelodyÌìÑÄ»ê
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 83.1
- É¢½ð: 100
- ºì»¨: 4
- Ìû×Ó: 179
- ÔÚÏß: 16.3Сʱ
- ³æºÅ: 1388081
- ×¢²á: 2011-09-02
- ÐÔ±ð: GG
- רҵ: »·¾³»¯Ñ§

4Â¥2012-07-02 11:17:43
crity328
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- DRDEPI: 1
- Ó¦Öú: 160 (¸ßÖÐÉú)
- ¹ó±ö: 1.292
- ½ð±Ò: 14059.9
- É¢½ð: 1149
- ºì»¨: 15
- ɳ·¢: 4
- Ìû×Ó: 1650
- ÔÚÏß: 315.9Сʱ
- ³æºÅ: 661953
- ×¢²á: 2008-11-25
- רҵ: Ò©Îï·ÖÎö

3Â¥2012-07-02 10:45:52
hardee
Ìú¸Ëľ³æ (ÖªÃû×÷¼Ò)
´Ë²ÝÓÐÖ÷~
- DRDEPI: 12
- Ó¦Öú: 152 (¸ßÖÐÉú)
- ¹ó±ö: 0.03
- ½ð±Ò: 10929.3
- É¢½ð: 5544
- ºì»¨: 49
- ɳ·¢: 40
- Ìû×Ó: 6865
- ÔÚÏß: 2905.6Сʱ
- ³æºÅ: 891544
- ×¢²á: 2009-11-02
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ

5Â¥2012-07-02 12:20:47
yugijiang
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 661 (²©Ê¿)
- ¹ó±ö: 0.005
- ½ð±Ò: 4018.4
- ºì»¨: 11
- Ìû×Ó: 1790
- ÔÚÏß: 178Сʱ
- ³æºÅ: 416091
- ×¢²á: 2007-06-29
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
mouse103: ½ð±Ò+1, лл²ÎÓë 2012-07-02 21:40:03
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
mouse103: ½ð±Ò+1, лл²ÎÓë 2012-07-02 21:40:03
|
USPÊÇÁ½¸öÔÓÖÊ£¬ÆäËûµÄÊÇ×÷Ϊµ¥¸öÔÓÖʺÍ×ÜÔÓÖÊÀ´¿ØÖƵġ£ Table 1 Name/ RRT AcceptanceCriteria/NMT (%) Celecoxib related compound Aa/ 0.9/ 0.4 Celecoxib /1.0 /¡ª Celecoxib related compound Bb/ 1.1 /0.10 Individual unspecified impurity /¡ª /0.10 Total impurities/ ¡ª /0.5 a 4-[5-(3-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. b 4-[3-(4-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. |
6Â¥2012-07-02 13:37:21













»Ø¸´´ËÂ¥